Blood, human or animal, antisera, other blood fractions and immunological products: n.e.c. in heading 3002.1

In 2021, blood, human or animal, antisera, other blood fractions and immunological products: n.e.c. in heading 3002.1 trade exhibited modest growth, with global flows reaching $2,936,462,544 and a three-year compound annual growth rate of -5.7% (five-year: +2.9%). The all-time peak of $5,814,145,980 was recorded in 2017; the current level is 49% below that high-water mark.

Over the 10-year observation window (2012–2021), 67% of years recorded positive growth, indicating a predominantly expanding market.

The supply side is diversified (Herfindahl-Hirschman Index 0.069). The three largest exporters — Italy ($368.3M), Switzerland ($334.7M), and United States ($255.0M) — collectively dominate supply flows. The leading exporter has grown at -11.6% over the last three years.

On the demand side, importer concentration is diversified (HHI 0.072). The three largest import markets are Russia ($485.2M), United States ($398.9M), and Italy ($284.7M). The largest importing market sources from 42 different supplying countries.

The dominant trade corridor is Switzerland → Russia at $229.6M, representing 47.3% of the importer's total demand.

The volatility score for blood, human or animal, antisera, other blood fractions and immunological products: n.e.c. in heading 3002.1 is 10 out of 100, classified as low. Trade flows are relatively stable compared to other HS6 products, suggesting mature supply chains and predictable demand.

For market entrants, modest but steady demand provides a reasonable entry window. The diversified supply landscape means many competitors but also multiple entry points and buyer relationships to target.

Data confidence is rated "Medium" based on reporting coverage and consistency across OECD member and partner countries.